LSTA Lisata Therapeutics, Inc. - Common Stock
$1.20
Price · Aug 19, 2026
Fundamentals as of Aug 6, 2026
52W Range
$1–$5
5% of range
Analyst Rating
BUY
9 analysts
Price Target
$4
+233% upside
P/E (TTM)
-1.0
ROE
—
Net Profit Margin
—
About Lisata Therapeutics, Inc. - Common Stock Company overview from Wikipedia
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
Read more
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide (also known as iRGD and CEND-1), orphan drug status in pancreatic cancer, followed by a Fast track (FDA) status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.
== References ==
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
LSTA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$1.20
Market Cap
—
P/E (TTM)
-1.0
EPS (TTM)
$-1.91
Revenue (TTM)
$170.0K
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$1 – $5
LSTA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
$170.0K
2016-12-31
→
2025-12-31
EPS
$-1.91
2016-12-31
→
2025-12-31
Free Cash Flow
—
2016-12-31
→
2023-12-31
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
LSTA
Peer Median
P/E (TTM)
-1.0
—
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
LSTA
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
LSTA
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
LSTA
Peer Median
Revenue YoY
-83.0%
—
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
LSTA
Peer Median
LSTA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
9 analysts
- Strong Buy 2 22.2%
- Buy 4 44.4%
- Hold 3 33.3%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
1 analysts · 2026-07-19
Low
$4.00
High
$4.00
Median target
$4.00
+233.3%
Mean target
$4.00
+233.3%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
0.10%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| Sept. 30, 2025 | $-0.49 | $-0.55 | 0.06% |
| June 30, 2025 | $-0.54 | $-0.66 | 0.12% |
| March 31, 2025 | $-0.55 | $-0.54 | -0.01% |
| Dec. 31, 2024 | $-0.55 | $-0.78 | 0.23% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| LSTA | — | -1.0 | -83.0% | — | — | — |
| INAB | $23M | -0.5 | — | — | -90.8% | — |
| OSRH | — | — | — | — | — | — |
| BIVI | — | — | — | — | — | — |
| LNAI | $513M | -2.7 | — | — | -586.4% | — |
| XCUR | $35M | -6.9 | — | — | -77.3% | — |
| MTVA | $19M | -1.1 | -44.6% | -2543.7% | -173.5% | — |
| VTGN | — | -0.3 | 161.1% | -5491.3% | -136.8% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 16
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $170.0K | $1M | $0 | $0 | · | · | · | · | · | $35M | |
| Cost of Revenue | · | · | · | · | · | · | · | · | · | $31M | |
| R&D Expense | · | · | · | · | $18M | $9M | $11M | $8M | $16M | $17M | |
| SG&A Expense | $10M | $12M | $13M | $14M | $11M | $10M | $9M | $9M | $12M | $13M | |
| Operating Expenses | $18M | $23M | $26M | $58M | $29M | $19M | $20M | $17M | $28M | $30M | |
| Operating Income | $-18M | $-22M | $-26M | $-58M | $-29M | $-19M | $-20M | $-17M | $-28M | $-30M | |
| Interest Expense | · | · | · | · | · | · | $0 | $5.0K | $378.0K | $2M | |
| Other Non-op | $-145.0K | $-257.0K | $-186.0K | $-155.0K | $-75.0K | $0 | $740.0K | $824.0K | $273.0K | $23.9K | |
| Pretax Income | $-18M | $-21M | $-23M | $-57M | $-29M | $-19M | $-19M | $-16M | $-28M | $-31M | |
| Income Tax | $-962.0K | $-798.0K | $-2M | $-2M | $-2M | $-11M | $0 | $0 | $-12M | $0 | |
| Net Income | $-17M | $-20M | $-21M | $-54M | $-27M | $-8M | $-19M | $-16M | $23M | $-33M | |
| EPS (Basic) | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 | $-0.53 | · | $-1.67 | $2.56 | $-4.99 | |
| EPS (Diluted) | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 | $-0.53 | · | · | $2.56 | $-4.99 | |
| Shares (Basic) | 8,687,000 | 8,329,000 | 8,073,000 | 5,180,000 | 3,688,000 | 15,440,000 | · | 9,689,000 | 8,969,000 | 6,548,251 | |
| Shares (Diluted) | 8,687,000 | 8,329,000 | 8,073,000 | 5,180,000 | 3,688,000 | 15,440,000 | · | 9,689,000 | 8,969,000 | 6,548,251 | |
| EBITDA | · | $-22M | $-26M | $-58M | · | $-19M | $-20M | $-17M | $-27M | $-30M |
Balance Sheet 30
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16M | $16M | $23M | $32M | $25M | $17M | $14M | $10M | $29M | $7M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $26M | $0 | |
| Receivables | $0 | $900.0K | $0 | · | · | · | · | · | $234.5K | $138.8K | |
| Prepaid Expense | $2M | $2M | $3M | $3M | $1M | $758.0K | $815.0K | $1M | $1M | $2M | |
| Current Assets | $18M | $35M | $54M | $72M | $96M | $35M | $26M | $44M | $61M | $25M | |
| PP&E (Net) | $18.0K | $72.0K | $175.0K | $296.0K | $62.0K | $57.0K | $100.0K | $165.0K | $257.0K | $705.4K | |
| PP&E (Gross) | $494.0K | $661.0K | $661.0K | $713.0K | $430.0K | $370.0K | $349.0K | $349.0K | $1M | $2M | |
| Accum. Depreciation | $476.0K | $589.0K | $486.0K | $417.0K | $368.0K | $313.0K | $249.0K | $184.0K | $832.0K | $1M | |
| Goodwill | · | · | · | · | · | · | · | · | · | $7M | |
| Intangibles | $400.0K | $400.0K | $400.0K | $400.0K | $0 | · | · | · | · | $2M | |
| Other Non-current Assets | $23.0K | $160.0K | $332.0K | $528.0K | $764.0K | $614.0K | $1M | $309.0K | $2M | $2M | |
| Total Assets | $18M | $35M | $55M | $73M | $97M | $36M | $27M | $45M | $63M | $54M | |
| Accounts Payable | $1M | $1M | $2M | $3M | $2M | $1M | $1M | $762.0K | $1M | $2M | |
| Accrued Liabilities | $2M | $4M | $4M | $4M | $3M | $2M | $4M | $5M | $8M | $3M | |
| Short-term Debt | · | · | · | · | · | · | · | $0 | $159.0K | $563.8K | |
| Current Liabilities | $3M | $6M | $7M | $6M | $5M | $4M | $6M | $6M | $9M | $21M | |
| Capital Leases | $0 | $0 | $137.0K | $305.0K | $485.0K | $254.0K | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $1M | |
| Other Non-current Liabilities | $72.0K | $72.0K | $210.0K | $327.0K | $485.0K | $254.0K | $624.0K | $2M | $4M | $389.9K | |
| Total Liabilities | $3M | $6M | $7M | $7M | $5M | $4M | $7M | $7M | $13M | $30M | |
| Long-term Debt | · | · | · | · | · | · | · | · | $0 | $6M | |
| Total Debt | · | · | · | · | · | · | · | $0 | $159.2K | $6M | |
| Common Stock | $9.0K | $8.0K | $8.0K | $8.0K | $4.0K | $19.0K | $11.0K | $10.0K | $9.0K | $8.2K | |
| Paid-in Capital | $580M | $578M | $577M | $575M | $546M | $459M | $439M | $436M | $433M | $410M | |
| Retained Earnings | $-565M | $-548M | $-528M | $-507M | $-453M | $-426M | $-417M | $-398M | $-382M | $-405M | |
| Treasury Stock | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $707.6K | |
| AOCI | $-37.0K | $-81.0K | $-42.0K | $-29.0K | $-70.0K | $-13.0K | $2.0K | $-32.0K | $-28.0K | $0 | |
| Stockholders' Equity | $15M | $30M | $48M | $67M | $92M | $32M | $21M | $38M | $51M | $5M | |
| Liabilities + Equity | $18M | $35M | $55M | $73M | $97M | $36M | $27M | $45M | $63M | $54M | |
| Shares Outstanding | 8,833,875 | 8,410,000 | 8,151,000 | 7,867,000 | 3,986,000 | 1,292,000 | 10,517,609 | 9,865,735 | 9,483,911 | 8,205,790 |
Cash Flow 16
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $146.0K | $174.0K | $189.0K | $69.0K | $55.0K | $100.0K | $100.0K | $200.0K | $400.0K | $500.0K | |
| Stock-based Comp | $1M | $2M | $2M | · | · | · | · | · | · | · | |
| Deferred Tax | $-962.0K | $-798.0K | $-2M | $-2M | $-2M | $-11M | $0 | $0 | $-576.0K | $0 | |
| Amort. of Intangibles | $65.0K | $71.0K | $71.0K | $21.0K | · | · | · | · | · | $570.0K | |
| Other Non-cash | · | · | $3M | $35M | · | $10M | $379.0K | $-4M | $-44M | $8M | |
| Operating Cash Flow | $-16M | $-19M | $-20M | $-21M | $-22M | $-9M | $-19M | $-20M | $-21M | $-24M | |
| CapEx | $28.0K | $0 | $0 | $285.0K | $60.0K | $20.0K | $0 | $134.0K | $135.0K | $1M | |
| Investing Cash Flow | $15M | $13M | $10M | $29M | $-55M | $-7M | $21M | $-5M | $41M | $-3M | |
| Net Debt Issued | · | · | · | · | · | · | · | $0 | $-6M | $-9M | |
| Stock Issued | $844.0K | $68.0K | $321.0K | $43.0K | $86M | $19M | · | · | · | · | |
| Net Stock Activity | · | $68.0K | $321.0K | $43.0K | · | · | · | · | · | · | |
| Financing Cash Flow | $599.0K | $-206.0K | $385.0K | $-224.0K | $85M | $19M | $1M | $824.0K | $-932.0K | $21M | |
| Net Change in Cash | $-253.0K | $-6M | $-10M | $8M | $8M | $2M | $4M | $-24M | · | $-6M | |
| Taxes Paid | $6.0K | $6.0K | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | $-20M | $-21M | · | $-9M | $-19M | $-20M | $-21M | $-27M | |
| Levered FCF | · | · | · | · | · | · | $-19M | $-20M | $-21M | $-28M |
Profitability 7
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -2240.9% | · | · | · | · | · | · | · | -88.8% | |
| Net Margin | · | -1998.5% | · | · | · | · | · | · | · | -94.4% | |
| Pretax Margin | · | -2078.3% | · | · | · | · | · | · | · | -94.0% | |
| EBITDA Margin | · | -2240.9% | · | · | · | · | · | · | · | -83.7% | |
| ROA | · | -44.6% | -32.6% | -63.8% | · | -25.8% | -54.0% | -29.9% | 39.3% | -57.9% | |
| ROE | · | -51.4% | -36.3% | -68.3% | · | -30.6% | -66.1% | -36.6% | 83.0% | -232.9% | |
| ROIC | · | -72.9% | -48.0% | -82.7% | · | -25.2% | -96.5% | -45.0% | -31.8% | -276.4% |
Liquidity & Solvency 5
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 6.2 | 8.2 | 11.3 | · | 10.1 | 4.3 | 7.8 | 6.6 | 1.3 | |
| Quick Ratio | · | 3.0 | 3.4 | 5.0 | · | 4.7 | 2.3 | 1.8 | 5.9 | 0.9 | |
| Debt / Equity | · | · | · | · | · | · | · | 0.0 | 0.0 | 1.3 | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | 0.0 | 0.5 | |
| Interest Coverage | · | · | · | · | · | · | · | -3397.4 | -73.0 | -16.9 |
Efficiency 2
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.0 | 0.0 | · | · | · | · | · | · | 0.6 | |
| Receivables Turnover | · | 2.2 | · | · | · | · | · | · | · | 12.9 |
Growth Rates 1
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -83.0% | · | · | · | · | · | · | · | · | · |
Valuation (TTM) 14
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $170.0K | $1M | $0 | $0 | $33M | $33M | $33M | $33M | $33M | $35M | |
| Net Income TTM | $-17M | $-20M | $-21M | $-54M | $-27M | $-8M | $-19M | $-16M | $23M | $-33M | |
| Market Cap | · | $25M | $22M | $20M | · | $416M | $396M | $527M | $499M | $348M | |
| Enterprise Value | · | · | · | · | · | · | · | $517M | $444M | $340M | |
| P/E | -1.0 | -1.2 | -1.1 | -0.2 | -1.7 | -40.5 | · | · | 20.6 | -8.5 | |
| P/S | · | 25.1 | · | · | · | 12.6 | 12.0 | 15.9 | 15.1 | 9.9 | |
| P/B | · | 0.8 | 0.5 | 0.3 | · | 12.8 | 19.0 | 14.0 | 9.9 | 71.3 | |
| P / Tangible Book | 1.1 | 0.9 | 0.5 | 0.3 | 8.2 | 12.8 | · | · | · | · | |
| P / Cash Flow | · | -1.3 | -1.1 | -0.9 | · | -47.1 | -21.0 | -26.4 | -23.9 | -14.7 | |
| P / FCF | · | · | -1.1 | -0.9 | · | -47.0 | -21.0 | -26.2 | -23.8 | -13.1 | |
| EV / EBITDA | · | · | · | · | · | · | · | -30.8 | -16.3 | -11.5 | |
| EV / FCF | · | · | · | · | · | · | · | -25.7 | -21.2 | -12.8 | |
| EV / Revenue | · | · | · | · | · | · | · | 15.6 | 13.5 | 9.6 | |
| Earnings Yield | -102.7% | -80.5% | -94.5% | -413.8% | -59.1% | -2.5% | · | · | 4.9% | -11.8% |
Income Statement 13
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $100.0K | $0 | $70.0K | $0 | $1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| SG&A Expense | $3M | $4M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $3M | $4M | |
| Operating Expenses | $4M | $5M | $3M | $4M | $5M | $6M | $6M | $5M | $6M | $7M | $6M | $6M | $7M | $7M | $7M | $38M | |
| Operating Income | $-4M | $-5M | $-3M | $-4M | $-5M | $-6M | $-5M | $-5M | $-6M | $-7M | $-6M | $-6M | $-7M | $-7M | $-7M | $-38M | |
| Other Non-op | $984.0K | $-54.0K | $-15.0K | $-18.0K | $-7.0K | $-105.0K | $-11.0K | $-45.0K | $-14.0K | $-187.0K | $-12.0K | $-11.0K | $-150.0K | $-13.0K | $-7.0K | $0 | |
| Pretax Income | $-3M | $-5M | $-3M | $-4M | $-5M | $-6M | $-5M | $-5M | $-5M | $-6M | $-5M | $-5M | $-6M | $-6M | $-6M | $-37M | |
| Income Tax | $0 | $-387.0K | $0 | $0 | $0 | $-962.0K | $0 | $0 | $0 | $-798.0K | $0 | $0 | $-2M | $0 | $0 | $0 | |
| Net Income | $-3M | $-4M | $-3M | $-4M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-4M | $-6M | $-6M | $-37M | |
| EPS (Basic) | $-0.32 | $-0.50 | $-0.33 | $-0.49 | $-0.54 | $-0.55 | $-0.55 | $-0.59 | $-0.61 | $-0.65 | $-0.66 | $-0.65 | $-0.50 | $-0.77 | $0.10 | $-7.88 | |
| EPS (Diluted) | $-0.32 | $-0.50 | $-0.33 | $-0.49 | $-0.54 | $-0.55 | $-0.55 | $-0.59 | $-0.61 | $-0.65 | $-0.66 | $-0.65 | $-0.50 | $-0.77 | $0.10 | $-7.88 | |
| Shares (Basic) | 9,106,000 | 9,006,000 | -17,258,000 | 8,738,000 | 8,605,000 | 8,602,000 | -16,594,000 | 8,321,000 | 8,308,000 | 8,294,000 | -16,076,000 | 8,141,000 | 8,021,000 | 7,987,000 | -7,639,000 | 4,747,000 | |
| Shares (Diluted) | 9,106,000 | 9,006,000 | -17,258,000 | 8,738,000 | 8,605,000 | 8,602,000 | -16,594,000 | 8,321,000 | 8,308,000 | 8,294,000 | -16,076,000 | 8,141,000 | 8,021,000 | 7,987,000 | -7,639,000 | 4,747,000 | |
| EBITDA | $-4M | $-5M | · | $-4M | $-5M | $-6M | · | $-5M | $-6M | $-7M | · | $-6M | $-7M | $-7M | · | $-38M |
Balance Sheet 24
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10M | $13M | $16M | $19M | $17M | $20M | $16M | $20M | $28M | $22M | $23M | $32M | $24M | $28M | $32M | $31M | |
| Receivables | · | · | $0 | · | · | · | $900.0K | · | · | · | $0 | · | · | · | · | · | |
| Prepaid Expense | $570.0K | $960.0K | $2M | $2M | $2M | $2M | $2M | $2M | $4M | $4M | $3M | $3M | $4M | $4M | $3M | $2M | |
| Current Assets | $11M | $14M | $18M | $22M | $25M | $29M | $35M | $38M | $42M | $48M | $54M | $57M | $61M | $65M | $72M | $77M | |
| PP&E (Net) | $14.0K | $16.0K | $18.0K | $22.0K | $48.0K | $74.0K | $72.0K | $96.0K | $119.0K | $146.0K | $175.0K | $204.0K | $233.0K | $262.0K | $296.0K | $299.0K | |
| PP&E (Gross) | $494.0K | $494.0K | $494.0K | $494.0K | $566.0K | $689.0K | $661.0K | $661.0K | $661.0K | $661.0K | $661.0K | $661.0K | $661.0K | $661.0K | $713.0K | · | |
| Accum. Depreciation | $480.0K | $478.0K | $476.0K | $472.0K | $518.0K | $615.0K | $589.0K | $565.0K | $542.0K | $515.0K | $486.0K | $457.0K | $428.0K | $399.0K | $417.0K | · | |
| Intangibles | $400.0K | $400.0K | $400.0K | $400.0K | $400.0K | $400.0K | · | $400.0K | $400.0K | $400.0K | · | $400.0K | $400.0K | $400.0K | · | $352.0K | |
| Other Non-current Assets | $0 | $23.0K | $23.0K | $23.0K | $70.0K | $116.0K | $160.0K | $201.0K | $246.0K | $290.0K | $332.0K | $371.0K | $410.0K | $449.0K | $528.0K | $588.0K | |
| Total Assets | $11M | $14M | $18M | $22M | $25M | $29M | $35M | $38M | $43M | $48M | $55M | $58M | $62M | $66M | $73M | $79M | |
| Accounts Payable | $836.0K | $510.0K | $1M | $619.0K | $782.0K | $602.0K | $1M | $556.0K | $728.0K | $1M | $2M | $1M | $775.0K | $1M | $3M | $974.0K | |
| Accrued Liabilities | $2M | $3M | $2M | $4M | $4M | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $5M | |
| Current Liabilities | $3M | $3M | $3M | $5M | $4M | $4M | $6M | $5M | $4M | $5M | $7M | $5M | $4M | $5M | $6M | $6M | |
| Capital Leases | · | · | $0 | · | · | · | $0 | $0 | $47.0K | $92.0K | $137.0K | $181.0K | $223.0K | $265.0K | $305.0K | $345.0K | |
| Other Non-current Liabilities | $50.0K | $72.0K | $72.0K | $72.0K | $72.0K | $72.0K | $72.0K | $72.0K | $119.0K | $164.0K | $210.0K | $253.0K | $295.0K | $337.0K | $327.0K | $367.0K | |
| Total Liabilities | $3M | $3M | $3M | $5M | $4M | $4M | $6M | $5M | $5M | $5M | $7M | $5M | $5M | $6M | $7M | $7M | |
| Common Stock | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | |
| Paid-in Capital | $581M | $581M | $580M | $580M | $579M | $579M | $578M | $578M | $578M | $577M | $577M | $576M | $576M | $575M | $575M | $574M | |
| Retained Earnings | $-572M | $-569M | $-565M | $-562M | $-557M | $-553M | $-548M | $-543M | $-539M | $-533M | $-528M | $-523M | $-517M | $-513M | $-507M | $-501M | |
| Treasury Stock | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | |
| AOCI | $-17.0K | $-21.0K | $-37.0K | $-42.0K | $-50.0K | $-78.0K | $-81.0K | $-32.0K | $-77.0K | $-104.0K | $-42.0K | $-100.0K | $-50.0K | $-52.0K | $-29.0K | $-90.0K | |
| Stockholders' Equity | $8M | $11M | $15M | $17M | $21M | $25M | $30M | $34M | $38M | $43M | $48M | $53M | $58M | $61M | $67M | $72M | |
| Liabilities + Equity | $11M | $14M | $18M | $22M | $25M | $29M | $35M | $38M | $43M | $48M | $55M | $58M | $62M | $66M | $73M | $79M | |
| Shares Outstanding | 9,119,004 | 9,107,291 | 8,833,875 | 8,755,948 | 8,626,464 | 8,620,162 | 8,408,844 | 8,319,600 | 8,321,061 | 8,307,433 | 8,149,897 | 8,139,449 | 8,132,357 | 7,998,342 | 7,866,061 | 7,862,602 |
Cash Flow 11
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3.0K | $2.0K | $15.0K | $44.0K | $44.0K | $43.0K | $41.0K | $42.0K | $45.0K | $46.0K | $47.0K | $47.0K | $47.0K | $48.0K | · | $8.0K | |
| Stock-based Comp | $214.0K | $364.0K | · | · | $239.0K | $530.0K | · | · | · | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $0 | $0 | $12.0K | $18.0K | $18.0K | $17.0K | $18.0K | $18.0K | $18.0K | $17.0K | $17.0K | $18.0K | $18.0K | $18.0K | $18.0K | · | |
| Operating Cash Flow | $-3M | $-3M | $-3M | $-3M | $-4M | $-5M | $-5M | $-3M | $-5M | $-7M | $-4M | $-4M | $-4M | $-8M | $-6M | $-4M | |
| CapEx | $0 | $0 | $0 | $0 | $0 | $28.0K | $0 | $0 | $0 | $0 | · | $0 | · | · | $26.0K | $24.0K | |
| Investing Cash Flow | $0 | $0 | $0 | $5M | $505.0K | $9M | $1M | $-6M | $12M | $6M | $-6M | $12M | $-725.0K | $4M | $7M | $2M | |
| Stock Issued | $29.0K | $0 | $205.0K | $353.0K | $74.0K | $212.0K | $36.0K | $0 | $32.0K | $0 | $24.0K | $0 | · | · | $14.0K | $0 | |
| Net Stock Activity | · | $0 | · | · | · | $212.0K | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $29.0K | $181.0K | $205.0K | $353.0K | $64.0K | $-23.0K | $-96.0K | $0 | $32.0K | $-142.0K | $24.0K | $-6.0K | $452.0K | $-85.0K | $14.0K | $-99.0K | |
| Net Change in Cash | $-3M | $-3M | $-3M | $2M | $-3M | $4M | $-3M | $-9M | $6M | $-788.0K | $-10M | $9M | $-4M | $-4M | $676.0K | $-2M | |
| Free Cash Flow | · | $-3M | · | · | · | $-5M | · | · | · | · | · | · | · | · | · | · |
Profitability 7
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | -6954.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Margin | · | · | · | · | -6655.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Pretax Margin | · | · | · | · | -6655.7% | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | · | · | · | · | -6954.3% | · | · | · | · | · | · | · | · | · | · | · | |
| ROA | -16.2% | -20.9% | · | -14.2% | -13.8% | -12.2% | · | -10.2% | -9.6% | -9.4% | · | -7.7% | -5.4% | -7.8% | · | -41.3% | |
| ROE | -20.0% | -24.8% | · | -16.6% | -15.7% | -13.8% | · | -11.4% | -10.5% | -10.4% | · | -8.4% | -5.7% | -8.3% | · | -43.8% | |
| ROIC | -48.4% | -41.6% | · | -25.4% | -23.2% | -19.2% | · | -15.8% | -14.4% | -13.4% | · | -11.3% | -7.5% | -11.2% | · | -52.4% |
Liquidity & Solvency 2
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 4.2 | · | 4.7 | 5.8 | 7.5 | · | 8.0 | 9.4 | 8.9 | · | 11.2 | 14.1 | 12.4 | · | 12.1 | |
| Quick Ratio | 3.5 | 3.9 | · | 4.2 | 3.9 | 5.3 | · | 4.2 | 6.3 | 4.1 | · | 6.3 | 5.4 | 5.3 | · | 4.9 |
Efficiency 1
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | · | · |
Valuation (TTM) 10
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $70.0K | $70.0K | · | $70.0K | $70.0K | $0 | · | $0 | $0 | $0 | · | $0 | · | · | · | · | |
| Net Income TTM | $-16M | $-18M | · | $-19M | $-19M | $-20M | · | $-21M | $-20M | $-21M | · | $-53M | $-54M | $-54M | · | $-55M | |
| Market Cap | $31M | $46M | · | $23M | $25M | $20M | · | $25M | $29M | $26M | · | $17M | $30M | $26M | · | $36M | |
| P/E | -1.8 | -2.4 | · | -1.2 | -1.3 | -1.0 | · | -1.2 | -1.4 | -1.2 | · | -0.2 | -0.3 | -0.3 | · | -0.4 | |
| P/S | 442.9 | 651.8 | · | 327.7 | 357.4 | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | 3.8 | 4.2 | · | 1.3 | 1.2 | 0.8 | · | 0.7 | 0.8 | 0.6 | · | 0.3 | 0.5 | 0.4 | · | 0.5 | |
| P / Tangible Book | 4.0 | 4.3 | · | 1.4 | 1.2 | 0.8 | · | 0.7 | 0.8 | 0.6 | · | 0.3 | 0.5 | 0.4 | · | 0.5 | |
| P / Cash Flow | · | -14.8 | · | · | · | -3.8 | · | · | · | -3.7 | · | · | · | -3.2 | · | · | |
| P / FCF | · | -14.8 | · | · | · | -3.7 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -54.4% | -41.5% | · | -82.8% | -79.0% | -102.1% | · | -83.3% | -69.5% | -82.4% | · | -457.9% | -291.6% | -348.9% | · | -265.9% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenue | $170.0K | $1M | $0 | $0 | — |
| Operating Margin % | — | -2240.9% | — | — | — |
| Net Income | $-17M | $-20M | $-21M | $-54M | $-27M |
| Diluted EPS | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 |
Balance Sheet
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Current Ratio | — | 6.2 | 8.2 | 11.3 | — |
| Quick Ratio | — | 3.0 | 3.4 | 5.0 | — |
Cash Flow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Free Cash Flow | — | — | $-20M | $-21M | — |
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 34 filers · $3.5M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 6 (-5 vs prior Q) | 5 (+1 vs prior Q) | 7 (+2 vs prior Q) | 5 (+3 vs prior Q) | +329K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $948,046 | 278,837 | 27.01% | Shares |
| Yakira Capital Management, Inc. | $471,107 | 138,561 | 13.42% | Shares |
| CSS LLC/IL | $375,435 | 110,422 | 10.70% | Shares |
| DELTEC ASSET MANAGEMENT LLC | $282,870 | 83,197 | 8.06% | Shares |
| Rangeley Capital, LLC | $275,400 | 81,000 | 7.85% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $195,517 | 57,490 | 5.57% | Shares |
| BlackRock, Inc. | $186,514 | 54,857 | 5.31% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $166,478 | 48,964 | 4.74% | Shares |
| GTS SECURITIES LLC | $102,680 | 30,200 | 2.93% | Shares |
| STATE STREET CORP | $86,183 | 25,348 | 2.46% | Shares |
| VANGUARD GROUP INC | $56,321 | 30,280 | 1.60% | Shares |
| CITADEL ADVISORS LLC | $52,839 | 15,541 | 1.51% | Shares |
| NORTHERN TRUST CORP | $52,816 | 15,534 | 1.50% | Shares |
| JBF Capital, Inc. | $48,780 | 14,347 | 1.39% | Shares |
| JANE STREET GROUP, LLC | $47,291 | 13,909 | 1.35% | Shares |
| BANK OF AMERICA CORP /DE/ | $35,200 | 10,353 | 1.00% | Shares |
| HighTower Advisors, LLC | $34,143 | 10,042 | 0.97% | Shares |
| SOL Capital Management CO | $29,342 | 12,175 | 0.84% | Shares |
| COOK WEALTH MANAGEMENT GROUP LLC | $29,342 | 12,175 | 0.84% | Shares |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | $16,800 | 5,000 | 0.48% | Shares |
| Founders Capital Management | $5,668 | 1,667 | 0.16% | Shares |
| Vanguard Global Advisers, LLC | $3,512 | 1,033 | 0.10% | Shares |
| Connective Capital Management, LLC | $3,454 | 1,016 | 0.10% | Shares |
| Tower Research Capital LLC (TRC) | $2,468 | 726 | 0.07% | Shares |
| OSAIC HOLDINGS, INC. | $680 | 200 | 0.02% | Shares |
| Caitong International Asset Management Co., Ltd | $306 | 90 | 0.01% | Shares |
| BARCLAYS PLC | $238 | 70 | 0.01% | Shares |
| MORGAN STANLEY | $228 | 67 | 0.01% | Shares |
| Virtu Financial LLC | $200 | 58,782 | 0.01% | Shares |
| Cerity Partners LLC | $27 | 8 | 0.00% | Shares |
| SBI Securities Co., Ltd. | $24 | 7 | 0.00% | Shares |
| Cheviot Value Management, LLC | $10 | 3 | 0.00% | Shares |
| Fortitude Family Office, LLC | $3 | 1 | 0.00% | Shares |
| ROYAL BANK OF CANADA | $0 | 39 | 0.00% | Shares |
Company insiders 43 insiders · 24 officers · 13 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Joseph Talamo | SVP and CFO | June 20, 2018 F | 35,210 | 0 | 0 | $0 |
| Robert S Vaters | President & CFO | Aug. 12, 2015 P | 228,750 | 0 | 0 | $0 |
| Robert Dickey IV | Chief Financial Officer | Dec. 31, 2014 A | 12,066 | 0 | 0 | $0 |
| Larry Alan May | Chief Financial Officer | Jan. 2, 2013 A | 64,618 | 0 | 0 | $0 |
| Hans Keirstead | President of the Issuer's NeoStem Oncology, LLC subsidiary. | May 9, 2014 A | — | 0 | 0 | $0 |
| Ian Zhang | President and Managing Director, NeoStem (China), Inc. | April 4, 2011 A | 10,000 | 0 | 0 | $0 |
| Mark Weinreb | President | May 21, 2009 A | 66,923 | 0 | 0 | $0 |
| Robert Joseph Aholt JR | Chief Operating Officer | Oct. 3, 2005 A | 4,369,317 | 0 | 0 | $0 |
| Douglas W Losordo | Executive Vice President, Global Head of Research and Development and Chief Medical Officer | June 20, 2018 F | 93,982 | 0 | 0 | $0 |
| Robin L Smith | Executive Chair of the Board | June 2, 2015 A | 347,285 | 0 | 0 | $0 |
| Catherine M Vaczy | General Counsel | April 13, 2015 A | 71,234 | 0 | 0 | $0 |
| Stephen W Potter | Executive Vice President | Dec. 31, 2014 A | 14,016 | 0 | 0 | $0 |
| Robert Dillman | Vice President, Oncology of the Issuer. The Reporting Person also serves as Chief Medical Officer of the Issuer's NeoStem Oncolo | May 9, 2014 A | — | 0 | 0 | $0 |
| Martin E Schmieg | Vice President - Corporate Dev | June 25, 2012 A | — | 0 | 0 | $0 |
| Jonathan Sackner-Bernstein | VP Clinical Dev & Reg Affairs | April 2, 2012 A | — | 0 | 0 | $0 |
| Jason Kolbert | VP of Strategic Business Development | Jan. 4, 2012 A | 8,000 | 0 | 0 | $0 |
| Mingsheng Shi | Chairman of the Board of Directors of Suzhou Erye Pharmaceutical Company Ltd., an entity 51%-owned by the Company. | Jan. 4, 2012 A | 3,650,770 | 0 | 0 | $0 |
| Alan G Harris | Vice President of Regenerative Medicine, Drug Development and Regulatory Affairs | April 4, 2011 A | — | 0 | 0 | $0 |
| Anthony Salerno | Vice President, Operations and Academic Affairs Exhibit List Exhibit 24 - Power of Attorney | June 9, 2010 A | — | 0 | 0 | $0 |
| Jian M Zhang | Vice President, Pharmaceutical Operations, and General Manager of Suzhou Erye Pharmaceuticals Company Ltd., a 51% owned subsidi | June 9, 2010 A | 3,650,770 | 0 | 0 | $0 |
| Christopher C Duignan | Vice President, Finance | Nov. 30, 2009 A | — | 0 | 0 | $0 |
| Lepore Teresa Linn Samuels | VP of Sales and Marketing | Oct. 29, 2009 A | — | 0 | 0 | $0 |
| Renee Cohen | VP of Oper. & Corp. Strategy | Feb. 27, 2008 A | 31,000 | 0 | 0 | $0 |
| Wayne A Marasco | Senior Scientific Advisor | June 2, 2006 A | 1,436,713 | 0 | 0 | $0 |
| Steven M Klosk | Director | Jan. 9, 2026 A | 95,815 | 0 | 0 | $0 |
| MYERS STEVEN S | Director | Jan. 10, 2022 A | 212,269 | 0 | 0 | $0 |
| Eric Wei | Director | Feb. 7, 2017 S | 172,223 | 0 | 0 | $0 |
| Richard J Berman | Director | Jan. 9, 2017 A | 7,177 | 0 | 0 | $0 |
| Andrew L Pecora | Director | June 22, 2016 A | 393,784 | 0 | 0 | $0 |
| Drew Bernstein | Director | June 2, 2015 A | 10,000 | 0 | 0 | $0 |
| Martyn D Greenacre | Director | June 2, 2015 A | 88,531 | 0 | 0 | $0 |
| Edward Geehr | Director | June 29, 2012 A | — | 0 | 0 | $0 |
| Joseph Zuckerman | Director | May 21, 2009 A | 41,260 | 0 | 0 | $0 |
| RimAsia Capital Partners Manager, Ltd. | 10% owner | Sept. 17, 2012 S | 105,306 | 0 | 0 | $0 |
| Gregory B Brown | — | Jan. 9, 2026 A | 95,659 | 0 | 0 | $0 |
| David J Mazzo | — | Jan. 9, 2026 A | 311,890 | 0 | 0 | $0 |
| Mohammad Azab | — | Jan. 9, 2026 A | 104,925 | 0 | 0 | $0 |
| Heidi Henson | — | Jan. 9, 2026 A | 85,725 | 0 | 0 | $0 |
| Erkki Ruoslahti | — | Jan. 9, 2023 A | 20,000 | 0 | 0 | $0 |
| Peter G Traber | — | Jan. 10, 2022 A | 149,190 | 0 | 0 | $0 |
| Anne Clem Whitaker | — | Nov. 1, 2020 A | 79,470 | 0 | 0 | $0 |
| Robert A Preti | — | May 18, 2017 F | 33,786 | 0 | 0 | $0 |
| Aholt Jr Family Trust | — | June 5, 2006 S | 12,352,227 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 20 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| RimAsia Capital Partners, L.P., RimAsia Capital Partners GP, L.P., RimAsia Capital Partners GP, Ltd., Eric H.C. Wei ×8 filings | May 20, 2010 | — | Initial filing | Passive investment | SEC |
| Robin L. Smith | Sept. 10, 2009 | — | Initial filing | Passive investment | SEC |
| Catherine M. Vaczy | Sept. 10, 2009 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Nov. 16, 2007 | — | Initial filing | — | SEC |
| Undisclosed reporting person | Oct. 30, 2007 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Feb. 20, 2007 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Jan. 5, 2007 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Dec. 15, 2006 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | June 29, 2006 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person, Undisclosed reporting person | June 29, 2006 | — | Initial filing | Passive investment | SEC |
| Mark Weinreb | June 29, 2006 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | June 28, 2006 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Dec. 8, 2005 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person, Undisclosed reporting person | Aug. 31, 2005 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Aug. 4, 2005 | — | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 4 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.